IART Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Integra Lifesciences Holdings Corp (IART) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock shows weak financial performance, inconsistent analyst sentiment, and no significant positive catalysts. Given the investor's preference for long-term investment, it is better to wait for clearer signs of recovery in financials and operational performance before considering entry.
The MACD is positive but contracting, RSI is neutral at 76.288, and moving averages are converging, suggesting no clear trend. The stock is trading near resistance levels (R1: 10.978) and has limited upside potential in the short term.
Underlying demand for Integra's regenerative tissue and specialty surgery products remains strong. Potential operational improvements in the second half of the year (e.g., Braintree operational by June) could act as a catalyst.
The company faces ongoing quality control issues in manufacturing, inconsistent operating performance, and declining financial metrics. Analysts have downgraded the stock and reduced price targets, citing structural challenges and execution overhangs.
In Q4 2025, revenue dropped by -1.74% YoY to $434.93M, net income fell to -$1.704M (-108.77% YoY), and EPS declined to -0.02 (-108.00% YoY). Gross margin also decreased to 57.02%, down -3.71% YoY.
Analysts have a mixed to negative sentiment on IART. Recent downgrades include Argus moving the stock to Hold from Buy, and Citi maintaining a Sell rating with a reduced price target of $9. Truist also lowered its price target to $12, citing execution risks and structural challenges.
